|Bid||55.08 x 800|
|Ask||55.11 x 1200|
|Day's Range||54.97 - 57.75|
|52 Week Range||26.02 - 57.82|
|Beta (3Y Monthly)||1.94|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 24, 2019 - Jul 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||54.40|
Is NovoCure Limited (NASDAQ:NVCR) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting for known risk attributes. […]
The cancer-focused medical-device maker received the go-ahead to enter a brand-new market. Here's why the news should make investors giddy.
In 2002 Asaf Danziger was appointed CEO of NovoCure Limited (NASDAQ:NVCR). This report will, first, examine the CEO...
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs May 23.) ArQule, Inc. (NASDAQ: ARQL ) Turning Point ...
Novocure (NVCR) announced today that Bill Doyle, Novocure’s Executive Chairman, will participate in the Jefferies 2019 Global Healthcare Conference on June 4, 2019, in New York City. Mr. Doyle will also participate in one-on-one meetings with investors throughout the day. A live audio webcast of the presentation can be accessed from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for replay for at least 14 days following the events.
Novocure (NVCR) today announced that the U.S. Food and Drug Administration (FDA) has approved the NovoTTF-100L System in combination with pemetrexed plus platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM). NovoTTF-100L is a non-invasive, antimitotic cancer treatment that delivers Tumor Treating Fields to the region of the tumor.
Novocure (NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have issued a proposed local coverage determination (LCD) that provides coverage of Tumor Treating Fields, or Optune, for newly diagnosed glioblastoma (GBM). Proposed LCDs are subject to a 45-day public comment period during which the DME MACs will consider feedback from patients, advocacy groups, prescribers and the general public prior to finalizing the LCD. The coverage policy criteria proposed by the DME MACs is generally similar to Optune’s commercial coverage criteria for newly diagnosed glioblastoma (GBM) with the exception of a proposed restriction on beneficiary site of care.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 1) Alcon AG (NYSE: ALC ) (announced presentation of new ...
NovoCure (NVCR) delivered earnings and revenue surprises of 0.00% and -0.44%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Saint Helier, Jersey-based company said it had a loss of 13 cents per share. The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was ...
Quarterly net revenues of $73.3 million, representing 41 percent growth versus the first quarter 2018 and 5 percent growth versus the fourth quarter 2018
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The most you can lose on any stock (assuming you don't use leverage) is 100% of your money...
The study provides a definition for Tumor Treating Fields dose and sets a framework for future work on Tumor Treating Fields dosimetry and treatment planning
On CNBC's "Mad Money Lightning Round," Jim Cramer said Entergy Corporation (NYSE: ETR ) is a big winner. He likes the company very much. Novocure Ltd (NASDAQ: NVCR ) is a good company and one ...
The market has been volatile in the fourth quarter as the Federal Reserve continued its rate hikes to normalize the interest rates. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by nearly 7 percentage points. SEC filings and hedge […]
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novocure (NVCR) announced today the publication of its 2018 Annual Report featuring its vision, mission and values, employee stories and videos, business highlights and selected financial information. In 2018, Novocure made a commitment to put into words its vision, mission and values as part of its corporate objective of investing in its people and culture.
Investors are always looking for growth in small-cap stocks like NovoCure Limited (NASDAQ:NVCR), with a market cap of US$4.4b. However, an important fact which most ignore is: how financially healthy is the business...